NovaBridge Biosciences NBP
0.88 USD -0.02 (-2.58%)
Regular-session close
0.90 +0.02 +2.30%
After hours · Nov 19, 5:40 PM ET
0.85 Day range 0.9033
0.751 52-week range 5.19
- YTD
- -77.89%
- 1 year
- -80.58%
News
benzinga.com NovaBridge’s Subsidiary Visara Doses First Patient In ASCEND Study, Randomized Phase 2b Trial To Evaluate VIS-101 In Patients With Wet Age-Related Macular Degeneration Head-to-head trial designed to evaluate VIS-101’s potential for sustained disease control with extended treatment intervalsPhase 2a results showed approximately 50% of patients in the 6 mg…
globenewswire.com Visara Announces First Patient Dosed in ASCEND Phase 2b Trial of VIS-101 in Wet AMD Head-to-head trial designed to evaluate VIS-101's potential for sustained disease control with extended treatment intervalsbenzinga.com NovaBridge’s Visara Enters Into Asset Purchase Option Agreement With YOLO Immune To Acquire Worldwide Rights To YOL104 Program And Develop, Commercialize YOL104-2 For Ocular Surface Squamous Neoplasia YOL104-2 is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic with the potential to be a first-in-class therapy for Ocular Surface Squamous Neoplasia…
